Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Activated leukocyte cell adhesion molecule (ALCAM), also known as CD166, is a type I transmembrane glycoprotein belonging to the immunoglobulin superfamily. It mediates both homophilic and heterophilic cell-cell interactions and is involved in various biological processes, including immune regulation, neural development, hematopoiesis, and cancer metastasis. ALCAM interacts with CD6 and LILRB4 to modulate T-cell activation and proliferation. It is implicated as a cancer stem cell marker and its expression correlates with enhanced invasion/metastasis in some cancers.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Activated leukocyte cell adhesion molecule (ALCAM).